How to write a scientific paper
Discussion) is the first level of composing a paper. Each of these parts must be structured accordingly. As examples, “Materials and Methods” must contain the right amount of informa tion (if too little is mentioned, no one can repeat the experiment; if too much is mentioned, it will be transformed into an instruction manual) and “Results” must contain as many numbers as possible, not duplicate data between text and tables / figures and not discuss the findings. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Dimitrios Goulis Tags: Abstract ID: 348 Source Type: research
What do editors check for before peer review
Editors want to publish honest reproducible data without data fabrication/ falsification/ duplication/ salami slice or plagiarism. Submissions need to comply to international guidelines and reporting standards. Thus, editors check submissions before they proceed to peer review. Initial screening consists of checking whether: the submission within the aims and scope of the journal, the cover letter is not for another journal, the manuscript complies with the guide for authors, the level of English is up to the standard expected by the journal and there is no significant overlap with other publications [iThenticate screening...
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Margaret Rees Tags: Abstract ID: 329 Source Type: research
The peer review process & Elsevier tools
After a first editorial screening, scientific manuscripts undergo the essential peer review process. Peer review is critical for the publication of robust and significant research and aims to be constructive, but it is sometimes a challenge for researchers to reach the final acceptance. Learn what to expect from peer review and how to improve your paper, how to be a reviewer yourself and support the scientific community, how editors make their decisions and the tools Elsevier provides to ensure ethical peer review. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Morgane Dagot Tags: Abstract ID: 325 Source Type: research
Vasomotor symptoms: modulation of the neurokinin 3 receptors
Vasomotor symptoms (VMS) are highly prevalent, up to 80%, among peri- and postmenopausal women. Their frequency and intensity may impose a considerable effect on the quality of life (QoL) of many subjects. There is strong evidence in favor of hormone therapy as the most appropriate option to control VMS. Research on the pathophysiology of VMS has shown that the mechanism consists of an increased sensitivity of the thermo-regulatory centre at the hypothalamus. The system is regulated by estrogens, and new data have shown the implication of the group of kisspeptin-neurokinin-dynorphin (KNDY) neurons. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Antonio Cano Tags: Abstract ID: 334 Source Type: research
AMH: the hormone of fertility and of menoapause
Anti-M üllerian Hormone (AMH) is produced by small antral follicles and has evolved over the past three decades as an assumed potential marker of the number of follicles in the human ovaries, also known as ovarian reserve. This quantitative measure, given the gradual decline over time and its non-replenis hable feature, could be the dreamed marker for predicting the final exhaustion of ovarian storage: the post-menopause. Reasons for this could be to manage age related infertility, but also to base a treatment strategy, such as ovarian surgery, on predicting the remaining years until the onset of men opause. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Frank J.M. Broekmans Tags: Abstract ID: 47 Source Type: research
EMAS at 25: meeting the challenges of WHI and beyond
EMAS has been founded 25 yrs ago to study Women's Health and to teach the management of the climacteric. Then, Hormone Therapy was used also to prevent chronic diseases, e.g. osteoporosis, cardiovascular diseases or dementia. In the US, the administration of oral CEE instead of oestradiol (E2), alone or combined with medroxy-progesterone-acetate (MPA), was standard and adopted for the Women's HeaIth Initiative (WHI) trial, a RCT. The mean age of its asymptomatic volunteers was 63 yrs at inclusion, beyond the "window of opportunity". (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Martin Birkhaeuser Tags: Abstract ID: 356 Source Type: research
Targeting women at risk of CVD at midlife: a challenge to the physician
The menopause transition is a period of accelerated cardiovascular disease risk. While menopause does not directly cause heart disease, several cardiometabolic changes occur due to declining estradiol and ovarian aging. Studies have demonstrated that lipoproteins dramatically increase the year before through the year after the final menstrual period, independent of the effect of aging alone. In addition, adverse changes in body fat distribution (central weight gain) increases the risk for metabolic syndrome and has been related to menopause transition independent of aging. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Chrisandra Shufelt Tags: Abstract ID: 218 Source Type: research
Teaching menopause to health care professionals
The menopause is a stage in the life cycle that affects all women. Managing perimenopausal and postmenopausal health is therefore a key issue for all healthcare professionals, not just gynecologists. The curriculum should include terminology and definitions, assessment, diagnosis and evidence-based management strategies. Healthcare professionals should be aware that women have different perceptions and experiences of the menopause which may be determined by: age and type of menopause, pre-existing health conditions, disability, employment and adverse childhood events. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Margaret Rees Tags: Abstract ID: 48 Source Type: research
The role of SERMs in menopausal hormonal treatment
Selective Estrogen Receptor Modulators (SERMs) are synthetic molecules that bind to the estrogen receptor and can have agonistic activity in some tissues while being antagonistic in others. While most clinicians are very familiar with older SERMs like tamoxifen and raloxifene, newer agents such as ospemifene and bazedoxifene offer other beneficial properties that should encourage their more widespread use to treat menopausal symptoms. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Steven R. Goldstein Tags: Abstract ID: 102 Source Type: research
Managing the menopause during the pandemic
The structure of the presentation will be (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Alfred Otto Mueck, Xiangyan Ruan Tags: Abstract ID: 101 Source Type: research
Migraine - a common but often missed symptom of perimenopause
Headache and migraine increase in prevalence during menopause but often go undiagnosed and are poorly managed. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: E. Anne MacGregor Tags: Abstract ID: 34 Source Type: research
Fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease (25-30% of the global adult general population) with no approved treatment to-date, although its treatment is attractive for the researchers and the pharmaceutical industry. The cessation of ovarian function (natural or iatrogenic menopause, premature ovarian insufficiency) is associated with increased abdominal adipose tissue and changes in carbohydrate and lipid metabolism. These changes lead to a dysmetabolic milieu, characterized by unfavorable lipid profile and the development of NAFLD, which may contribute to the increase in cardiovascular risk ob...
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Stergios Polyzos Tags: Abstract ID: 139 Source Type: research
MHT in women with endometriosis
The relation between Menopausal Hormonal Treatment MHT and endometriosis rises several debates in relation with the characteristics of each. From the point of view of view of MHT the individualized balance of risks and benefits, which seems to be the key of the approach of this therapy should be apply in each and every case. The profile of a women with a symptomatic endometriosis, in generally marked by pain, infertility and/or several series surgeries in the pelvic area, might be one marked by an early menopause, symptomatic and with several risks related to menopausal syndrome, osteoporosis and poor quality of life, whic...
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Iuliana Ceausu Tags: Abstract ID: 379 Source Type: research
Polypharmacy and cognition in older women: less is more?
At present, two-thirds of all community-dwelling adults develop multiple non-communicable diseases in their lifetime, with women at nearly double the risk of multimorbidity involving psychiatric conditions than men. This high burden of somatic-psychiatric multimorbidity among women necessitates frequent and simultaneous use of drugs according to various disease-specific guidelines. This do not necessarily imply overtreatment as co-occurring diseases may warrant treatment by multiple drugs, yet when inappropriate, polypharmacy turns to be particularly detrimental to cognitive health among older women. (Source: Maturitas)
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Silvan Licher Tags: Abstract ID: 158 Source Type: research
Strategies to prevent cognitive decline after menopause
Cognitive decline after menopause is highly heterogenous. It is uncertain whether what type, or amount, of cognitive decline associated with ageing is physiologically normal. The major risk factor for the most serious form of cognitive decline, dementia, is age itself, with the risk doubling for every 5 years past the age of 60. Dementia is much more age dependent as opposed to the more common condition, Minor Neurocognitive Disorder (MCD) (previously called Mild Cognitive Impairment). MCD may occur in around 20% of people over the age of 60 years but progression to dementia is relatively uncommon and many people with MCD ...
Source: Maturitas - June 8, 2023 Category: Primary Care Authors: Leon Flicker Tags: Abstract ID: 62 Source Type: research
